Later in 2021, Conforti et al. [27] also assessed sex-based heterogeneity specifically in survival after immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway for non-small-cell lung cancer expressing high PD-L1 levels in another systematic review and meta-analysis that included 1672 patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.